Drugs / ORN252
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT07439796 | Mar → Dec 2026 expected | — | Orna Therapeutics, Inc. | Recruiting | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | ORN252 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07439796 ↗ |
| Modality | Other / unclassified | “circular RNA” NCT07439796 ↗ |
| Target | CD19 | “anti-CD19 CAR protein” NCT07439796 ↗ |